Blog Posts
Daniel Flora
Daniel Flora/accru.org

Daniel Flora: T-cell inhibition plus hypomethylation for locally advanced HER2-negative breast cancer

Daniel Flora, Medical Director of Oncology Research at St. Elizabeth Healthcare, shared a paper he and his colleagues authored on LinkedIn:

“Thanks to St Elizabeth patients who participated in this clinical trial helping us find new ways to target breast cancer with immunotherapy. Also super cool to share authorship with my Emory University bud and rockstar oncologist Andrew Poklepovic.”

T-cell immune checkpoint inhibition plus hypomethylation for locally advanced HER2-negative breast cancer: a phase 2 neoadjuvant window trial of decitabine and pembrolizumab followed by standard neoadjuvant chemotherapy

Authors: Harry D Bear et al.

Daniel Flora: T-cell inhibition plus hypomethylation for locally advanced HER2-negative breast cancer

cancer Daniel Flora HER2-negative breast cancer OncoDaily Oncology